Mag 8: Could Lilly be the first trillion dollar pharma stock?
This article is so good
it's for premium members only.
Does that sound like you?
PREMIUM
ONLY $30/MONTH
BILLED ANNUALLY OR $35 MONTHLY
All BASIC features, plus:
- Premium Articles: Dive into subscriber-only content, market analysis, and insights that keep you ahead of the game.
- Access to our Private X Account, The Market Ear analysis, and Newsquawk
- Ad-Free Experience: Enjoy an uninterrupted browsing experience.
PROFESSIONAL
ONLY $125/MONTH
BILLED ANNUALLY OR $150 MONTHLY
All PREMIUM features, plus:
- Research Catalog: Access to our constantly updated research database, via a private Dropbox account (including hedge fund letters, research reports and analyses from all the top Wall Street banks)
Trillion dollar baby
Every thing is going Eli Lilly's way lately. New all-time highs on a regular basis and up>30% YTD. Investors are now switching focus to what the upside potential is. Morgan Stanley this week raised price target to a Wall Street-high of $950 and asked if LLY could be the first $1 trillion pharma stock. Goldman also sees potential to breach the trillion dollar mark and makes a convincing case for LLY to join the Magnificent club. Let's dig in more on the product that >30% of all Americans should be on and the stock that we all should own.